Forensic science meets clinical pharmacology: pharmacokinetic model based estimation of alcohol concentration of a defendant as requested by a local prosecutor’s office

Hyeong-Seok Lim¹, Jea Hyen Soung² and Kyun-Seop Bae¹*
¹Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Ulsan University College of Medicine, Seoul 05505, Republic of Korea, ²Center of International Cooperation, Korean Institute of Criminology, Seoul 06764, Republic of Korea
*Correspondence: K.S. Bae; Tel: +82-2-3010-4611, Fax: +82-2-3010-4623, E-mail: ksbae@amc.seoul.kr

Drunk driving is a serious social problem. We estimated the blood alcohol concentration of a defendant on the request of local prosecutor’s office in Korea. Based on the defendant’s history, and a previously constructed pharmacokinetic model for alcohol, we estimated the possible alcohol concentration over time during his driving using a Bayesian method implemented in NONMEM®. To ensure generalizability and to take the parameter uncertainty of the alcohol pharmacokinetic models into account, a non-parametric bootstrap with 1,000 replicates was applied to the Bayesian estimations. The current analysis enabled the prediction of the defendant’s possible blood alcohol concentrations over time with a 95% prediction interval. The results showed a high probability that the alcohol concentration was ≥ 0.05% during driving. The current estimation of the alcohol concentration during driving by the Bayesian method could be used as scientific evidence during court trials.

Introduction

According to Korean law, drunk driving refers to driving with a blood alcohol concentration of 0.05 % or higher. Drunk driving is one of three major traffic violations together with hit-and-run and unlicensed driving. Although the overall incidence of traffic accidents has been decreasing steadily in Korea because of stricter regulations, and aggressive enforcement by police, the incidence of accidents resulting from drunk driving has not decreased.[1]

In 2012, a Korean local prosecutor’s office requested the Department of Clinical Pharmacology and Therapeutics of Asan Medical Center, Ulsan University to estimate the blood alcohol concentration of a defendant during driving. The defendant was suspected of drunk driving. However, the suspect’s blood alcohol concentration was measured after he had finished the driving using a breath alcohol test. The suspect stated that he had consumed four cups of soju at an average rate over a period of about 30 minutes just before driving. Blood alcohol concentration measured at 1 hour 24 minutes after the end of alcohol drinking over 30 minutes was 0.173%, as estimated by the alcohol breath test.

In this study, modeling and simulation analysis estimated the possible alcohol concentration in blood over time while the defendant was driving using a Bayesian method based on the alcohol consumption history reported by the defendant, blood alcohol concentration measured by the alcohol breath test, and a population pharmacokinetic (PK) model of alcohol, previously developed for Korean adult males. This approach provided scientific evidence of the defendant’s blood alcohol concentration during a specific time window, which could be useful during prosecutions for drunk driving.

Methods

An alcohol PK model (Original, Alcohol PK Model, OAPKM), previously developed using 178 blood alcohol concentrations (%) measured by the breath alcohol test from 24 healthy, Korean adult males in a phase 1 clinical trial (Table 1), was used in...
Table 1. Pharmacokinetic parameter estimates of alcohol concentration (%) after drinking alcohol (32 mg) in 24 healthy male volunteers

| Parameter | Estimate | 95% CI | Bootstrap Median | Bootstrap 95% CI |
|-----------|----------|--------|------------------|------------------|
| $K_a$, 1/hour | 5.62 | 2.39 – 8.85 | 5.82 | 3.37 – 16.51 |
| IIIV$_{K_a}$ (CV %) | 1.420 (177.1) | 0.49 – 2.35 | 1.463 (182.2) | 0.66 – 3.38 |
| $V$, L | 372.00 | 342.60 – 401.40 | 370.98 | 341.42 – 410.48 |
| IIIV$_v$ (CV %) | 0.026 (35.7) | 0.001 – 0.051 | 0.023 (15.4) | 0.001 – 0.056 |
| $V_{\text{max}}$, %/hour | 72.40 | -68.52 – 213.32 | 75.80 | 14.80 – 93638.79 |
| IIIV$_{\text{max}}$ (CV %) | 1.090 (40.1) | -0.948 – 3.128 | 0.666 | 0.083 – 6.943 |
| $K_m$ | 0.47 | -0.56 – 1.50 | 0.50 | 0.05 – 719.42 |
| IIIV$_{K_m}$ (CV %) | 0.416 (71.8) | -0.031 – 0.863 | 0.758 | 0.085 – 7.542 |
| $\varepsilon$ (additive), % | 0.005 | 0.004 – 0.005 | 0.004 | 0.15 – 0.31 |
| $\varepsilon^*$ (proportional) | 0.041* | 0.006 – 0.076 | 0.041* | 0.00 – 0.07 |

Abbreviations: IIIV, inter-individual variability; CV, coefficient of variation; $K_a$, absorption rate constant; $V$, volume of distribution; $V_{\text{max}}$, maximum alcohol elimination rate; $K_m$, alcohol concentration at the half of $V_{\text{max}}$, CI, confidence interval, $V$ and $V_{\text{max}}$ are typical values in subjects weighing 70 kg, since they are expressed in the form of $V = V(70)*(\text{WT}/70)$, and $V_{\text{max}} = V_{\text{max}}(70)*(\text{WT}/70)$, respectively, where $V(70)$ and $V_{\text{max}}(70)$ are typical values for individuals weighing 70 kg. $^*$ represents the standard deviation.

The process, SUPERPROBLEM in NONMEM was used, and repetitive batch processing including bootstrap data generation, NONMEM fitting, and Bayesian estimation were performed using R (version 3.01).

Results

The bootstrap result of the original alcohol PK model from 24 healthy, Korean male, subjects was similar to the original PK parameter estimates of the single run in terms of median and the 95% confidence interval, suggesting that the resultant individual PK parameter estimates were reasonable (Table 1). The MAP estimates of the alcohol PK parameters of the defendant (MAPIP) were different from the PK parameters of the OAPKM. $V_{\text{max}}$ and alcohol concentration at half of $V_{\text{max}}$ ($K_m$) in

Table 2. Maximum a posteriori (MAP) Bayesian Individual alcohol pharmacokinetic parameters of the defendant

| Parameter | Median | 95% CI |
|-----------|--------|--------|
| $K_a$, 1/hour | 2.50 | 2.08 – 5.88 |
| $V$, L | 143.09 | 112.00 – 416.06 |
| $V_{\text{max}}$, %/hour | 604.30 | 0.70 – 10986570000.00 |
| $K_m$, % | 14.31 | 0.00 – 210444250.00 |

Abbreviations: $K_a$, absorption rate constant; $V$, volume of distribution; $V_{\text{max}}$, maximum alcohol elimination rate; $K_m$, alcohol concentration at the half of $V_{\text{max}}$, CI, confidence interval.

*The pharmacokinetic parameters of the defendant were estimated by performing 1,000 Bayesian estimations, based on the bootstrap pharmacokinetic parameters, which were obtained from 1,000 different bootstrap samples from the original pharmacokinetic data, the defendant’s statement that he drank four cups of soju, and blood alcohol concentration (%) estimated by the breath alcohol test.
Figure 1. Overall Study Flow Diagram.  
*Abbreviations: PK, pharmacokinetics; MAP, Maximum a posteriori; OAPKM, Original Alcohol PK model; BAPPKP, Alcohol Population PK Parameter from bootstrapping; MAPIPKP, PK Parameter estimated from MAP Bayesian Method.

Figure 2. Blood alcohol concentrations (%) over time predicted by the Bayesian method.

The Michaelis-Menten equation constituting the OAPKM were considerably larger, while \( K_a \) and \( V_d \) were smaller than those in the OAPKM (Table 2). The MAPIPKP was used to create a blood alcohol concentration profile over time, and the result is shown with median and the 95% prediction interval (Fig. 2). The results showed a high probability that the blood alcohol concentration of the defendant was \( \geq 0.05 \% \) during driving (Table 3).
In the present analysis, the blood alcohol concentration profile of a defendant suspected of drunk driving was estimated using a previous alcohol PK model and the defendant's-specific information. In some replicates of this bootstrap-Bayesian estimation analysis, estimation by NONMEM was terminated or individual Bayesian PK parameter estimates of the defendant (MAPIPKP) were unrealistic. We included all these terminated and unrealistic bootstrap results in the analysis. The minimization termination status of NONMEM has been reported to affect minimally the bootstrap result in previous studies.[7,8] Concerning the unrealistic PK parameter values of the defendant obtained during this analysis, we suggest that they were due to the inaccuracy of the defendant's statement about his alcohol consumption, rather than to a problem in parameter estimation.

MAPIPKP differed from those of healthy normal volunteers (parameters in OAPKM), and the blood alcohol concentrations of the defendant measured by the breath alcohol test were higher than the upper limit of the 95% prediction interval for blood alcohol concentration (Fig. 2). Specifically, the $K_m$ in the MAPIPKP was approximately 30-fold higher than that in OAP-KM (14.31% vs. 0.47%), whereas the $V_{max}$ was only 9-fold higher (compared to 30-fold higher $K_m$) in the MAPIPKP (604.30%/hour vs. 72.40%/hour). These results indicate that the alcohol elimination rate ($C_{max}/(K_m + C_i)$, where $C_i$ is alcohol concentration) of the defendant was much lower than that of an average healthy, Korean, adult male, which would be rare. One possible explanation is that the amount of alcohol consumption stated by the defendant was lower than the actual one. The defendant could have under-reported the amount of alcohol he consumed, in which case the PK parameters estimated by the Bayesian methods would be biased.

The current Bayesian approach to estimate blood alcohol concentrations during driving provides a good example of the application of PK modeling and simulation to an area other than patient treatment or drug development. The estimated alcohol concentrations provide scientific evidence that could be useful in a trial. The present analysis could represent a starting point for the application of quantitative clinical pharmacology principles to social areas outside medicine.

**Discussion**

In the present analysis, the blood alcohol concentration profile of a defendant suspected of drunk driving was estimated using a previous alcohol PK model and the defendant’s-specific information.

In some replicates of this bootstrap-Bayesian estimation analysis, estimation by NONMEM was terminated or individual Bayesian PK parameter estimates of the defendant (MAPIPKP) were unrealistic. We included all these terminated and unrealistic bootstrap results in the analysis. The minimization termination status of NONMEM has been reported to affect minimally the bootstrap result in previous studies.[7,8] Concerning the unrealistic PK parameter values of the defendant obtained during this analysis, we suggest that they were due to the inaccuracy of the defendant’s statement about his alcohol consumption, rather than to a problem in parameter estimation.

MAPIPKP differed from those of healthy normal volunteers (parameters in OAPKM), and the blood alcohol concentrations of the defendant measured by the breath alcohol test were higher than the upper limit of the 95% prediction interval for blood alcohol concentration (Fig. 2). Specifically, the $K_m$ in the MAPIPKP was approximately 30-fold higher than that in OAP-KM (14.31% vs. 0.47%), whereas the $V_{max}$ was only 9-fold higher (compared to 30-fold higher $K_m$) in the MAPIPKP (604.30%/hour vs. 72.40%/hour). These results indicate that the alcohol elimination rate ($C_{max}/(K_m + C_i)$, where $C_i$ is alcohol concentration) of the defendant was much lower than that of an average healthy, Korean, adult male, which would be rare. One possible explanation is that the amount of alcohol consumption stated by the defendant was lower than the actual one. The defendant could have under-reported the amount of alcohol he consumed, in which case the PK parameters estimated by the Bayesian methods would be biased.

The current Bayesian approach to estimate blood alcohol concentrations during driving provides a good example of the application of PK modeling and simulation to an area other than patient treatment or drug development. The estimated alcohol concentrations provide scientific evidence that could be useful in a trial. The present analysis could represent a starting point for the application of quantitative clinical pharmacology principles to social areas outside medicine.

**Acknowledgements**

The authors have nothing to declare.

**Table 3. Estimated blood alcohol concentrations over time in the defendant**

| Time after the onset of alcohol consumption, hour | Percentage of alcohol concentration ≥ 0.05 % | Median alcohol concentration, % | Lower bound of the 95% PI for alcohol concentration, % | Upper bound of the 95% PI for alcohol concentration, % |
|--------------------------------------------------|--------------------------------------------|--------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| 0                                                | 0                                          | 0                              | 0                                                      | 0                                                      |
| 0.17                                             | 0.019624                                   | 0.008011                       | 0.025786                                               | 0.103403                                               |
| 0.33                                             | 0.049542                                   | 0.02024                        | 0.061043                                               | 0.149347                                               |
| 0.5                                              | 0.088048                                   | 0.035944                       | 0.103403                                               | 0.149347                                               |
| 0.58                                             | 0.110615                                   | 0.04517                        | 0.129572                                               | 0.149347                                               |
| 0.67                                             | 0.129615                                   | 0.052606                       | 0.149347                                               | 0.149347                                               |
| 0.75                                             | 0.14208                                    | 0.057973                       | 0.161822                                               | 0.161822                                               |
| 0.83                                             | 0.15129                                    | 0.061172                       | 0.172033                                               | 0.172033                                               |
| 0.92                                             | 0.158545                                   | 0.064203                       | 0.179522                                               | 0.179522                                               |
| 1                                                | 0.16292                                    | 0.066101                       | 0.18469                                                | 0.18469                                                |
| 1.1                                              | 0.166265                                   | 0.067671                       | 0.188501                                               | 0.188501                                               |
| 1.2                                              | 0.167835                                   | 0.068383                       | 0.189984                                               | 0.189984                                               |
| 1.3                                              | 0.16792                                    | 0.068663                       | 0.189863                                               | 0.189863                                               |
| 1.4                                              | 0.16702                                    | 0.068719                       | 0.18801                                                | 0.18801                                                |
| 1.5                                              | 0.165515                                   | 0.068522                       | 0.185216                                               | 0.185216                                               |
| 1.6                                              | 0.16314                                    | 0.06802                        | 0.181512                                               | 0.181512                                               |
| 1.7                                              | 0.160255                                   | 0.067358                       | 0.177291                                               | 0.177291                                               |

Abbreviations: PI, prediction interval.

**The current estimations are based on the defendant’s body weight, the statement that he drank four cups of soju on average over 30 minutes, and the blood alcohol concentration estimated by the breath alcohol test.**
Conflict of interest
The authors declare they have no conflict of interest.

References
1. KoROAD webzine. Retrieved from http://news.koroad.or.kr/articleview.php?id=112 Accessed November 25 2016
2. Bruno R, Iliadis A, Botta A, Mariotti B, Julien G, Cano JP. Pharmacokinetic study of ethanol after oral administration: a new approach to enzymatic elimination. Int J Clin Pharmacol Ther Toxicol 1983;21:363-369.
3. Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet 2012;51:187-201. doi: 10.2165/1159990-000000000-00000.
4. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, Bernard N, Thiry P, Le Meur Y, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 2006;45:905-922.
5. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999;59:19-29.
6. Parke J, Charles BG. Factors affecting oral ciclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol 2000;56:481-487.
7. Holford NH, Kirkpatrick C, Duffull D. NONMEM Termination status is not an important indicator of the quality of bootstrap parameter estimates. PAGE 2006;Abstr 992. http://www.page-meeting.org/default.asp?abstract=992 Accessed November 25 2016
8. Gastonguay MR, El-Tahtawy A. Effect of NONMEM minimization status and number of replicates on bootstrap parameter distributions for population pharmacokinetic models: a case study. Clin Pharmacol Ther 2005;77:P2-P2.